全体要約
2023年の複合ホルモン避妊薬市場は174億ドルと評価され、2030年には220億ドルに達する見込みで、年平均成長率は3.4%です。
複合ホルモン避妊薬は妊娠防止に加え、にきびや子宮内膜症、多嚢胞性卵巣症候群の治療にも使用され、主に15歳から49歳の女性に広く利用されています。
市場の成長には、製品の差別化やコスト削減、サプライチェーンの最適化が重要です。企業は研究開発に投資し、戦略的パートナーシップを結び、消費者のニーズに応じた製品を提供する必要があります。
関連する質問
17400 million USD (2023年)
3.4% (2023年から2030年)
Actavis, Agile Therapeutics, Allergan, Bayer, Teva Pharmaceutical Industries, ANI Pharmaceuticals, Ortho-McNeil-Janssen Pharmaceuticals, Noven Pharmaceuticals, Johnson & Johnson, Mylan
製品の差別化, コスト削減, サプライチェーンの最適化
概要
研究報告は、世界の複合ホルモン避妊薬市場の成長可能性を強調しています。複合ホルモン避妊薬は、今後の市場で安定した成長を示すことが期待されています。しかし、製品の差別化、コスト削減、供給チェーンの最適化は、複合ホルモン避妊薬の普及にとって重要な要素のままです。市場プレーヤーは、研究開発に投資し、戦略的パートナーシップを結び、進化する消費者の好みに沿った提供を整える必要があります。これにより、複合ホルモン避妊薬市場がもたらす膨大な機会を活用することができます。
複合ホルモン避妊薬は、妊娠を防ぐために使用されます。また、排卵をブロックすることによって、尋常性ざ瘡、子宮内膜症、多嚢胞性卵巣症候群、不規則な月経の治療にも使用されます。これらの製品は、15歳から49歳までの女性によって広く使用されています。
2022年の世界の製薬市場は1475億USDであり、次の6年間で年平均成長率（CAGR）5％で成長すると予測されています。製薬市場には化学医薬品と生物医薬品が含まれています。生物医薬品は2022年に381億USDに達すると予想されています。対照的に、化学医薬品市場は2018年の1005億USDから2022年には1094億USDに増加すると推定されています。製薬市場の要因には、医療に対する需要の増加、技術の進歩、慢性疾患の有病率の上昇、製薬製造セグメントの発展のための民間および政府機関からの資金増加、医薬品の研究開発活動の増加があります。しかし、業界は厳しい規制、高い研究開発コスト、特許の期限切れなどの課題にも直面しています。企業は市場で競争力を保ち、製品が必要とする患者に届くようにするために、継続的に革新し、これらの課題に適応する必要があります。さらに、COVID-19パンデミックはワクチン開発とサプライチェーン管理の重要性を強調し、製薬会社が新たな公衆衛生のニーズに迅速かつ柔軟に対応する必要性をさらに強調しています。
主要な特徴：
コンバインドホルモナルコントラセプティブ市場に関する報告は、さまざまな側面を反映し、業界に貴重な洞察を提供します。
市場規模と成長：この調査報告書は、合わせホルモン避妊薬市場の現在の規模と成長の概要を提供します。歴史的データ、タイプ別の市場セグメンテーション（例：15-24歳、25-34歳）、地域別の内訳が含まれる可能性があります。
市場のドライバーと課題：この報告書では、政府の規制、環境への懸念、技術の進歩、消費者の好みの変化など、コンバインドホルモン避妊薬市場の成長を促進する要因を特定し、分析することができます。また、業界が直面する課題も強調することができ、インフラの制限、航続距離不安、高い初期コストなどが含まれます。
競争環境：この調査報告書は、コンバインドホルモン避妊薬市場の競争環境に関する分析を提供します。主要企業のプロフィール、市場シェア、戦略、および製品提供が含まれています。また、報告書は新興企業の紹介とその市場への潜在的な影響についても強調できます。
技術的進展：この研究報告は、コンビネーションホルモン避妊薬業界における最新の技術的進展を詳しく探求できます。これには、コンビネーションホルモン避妊薬の技術の進歩、新しい参入者、新しい投資、およびコンビネーションホルモン避妊薬の未来を形作るその他の革新が含まれます。
下流の購入者の好み：このレポートは、複合ホルモン避妊薬市場における顧客の購入行動と採用トレンドについての洞察を提供することができます。それには、顧客の購買決定に影響を与える要因や、複合ホルモン避妊薬製品の好みが含まれています。
政府の政策とインセンティブ：研究報告書は、コンバインドホルモナルコントラセプティブ市場に対する政府の政策およびインセンティブの影響を分析します。これには、規制の枠組み、補助金、税制上のインセンティブ、及びコンバインドホルモナルコントラセプティブ市場の促進を目的としたその他の措置の評価が含まれる場合があります。また、報告書は、市場の成長を促進する上でのこれらの政策の有効性も評価しています。
環境影響と持続可能性：この研究報告は、複合ホルモン避妊薬市場の環境影響と持続可能性の側面を評価しています。
市場予測と将来の見通し: 実施された分析に基づき、研究報告書は組み合わせホルモン避妊薬業界の市場予測と見通しを提供します。これには、市場規模、成長率、地域トレンド、技術進歩および政策の発展に関する予測が含まれます。
推奨事項と機会：レポートは、業界の利害関係者、政策立案者、投資家への推奨で締めくくられています。新たなトレンドを活用し、課題を克服し、コンバインドホルモン避妊薬市場の成長と発展に貢献するための市場参入者にとっての潜在的な機会を強調しています。
市場セグメンテーション:
複合ホルモン避妊薬市場は、タイプ別およびアプリケーション別に分割されています。2019年から2030年の期間において、セグメント間の成長は、量と価値の観点から、タイプ別およびアプリケーション別の消費価値の正確な計算と予測を提供します。
タイプ別セグメンテーション
15-24歳
25-34歳
35-44歳
44歳以上
用途別のセグメンテーション
病院薬局
小売薬局
オンライン薬局
このレポートは市場を地域別に分けています：
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下のプロファイルされた企業は、一次専門家から収集された情報と、企業のカバレッジ、製品ポートフォリオ、市場浸透の分析に基づいて選定されました。
アクタビス
アジャイル・セラピューティクス
アラガン
バイエル
テバ製薬工業
ANIファーマシューティカルズ
オルソ-マクニール-ヤンセン製薬
ノーベン・ファーマシューティカルズ
ジョンソン・エンド・ジョンソン
マイラン
本報告書で扱われる主な質問
グローバルコンバインドホルモン避妊薬市場の10年の見通しは何ですか？
コンバインドホルモナル避妊薬の市場成長を推進している要因は何ですか、グローバルおよび地域別に？
どの技術が市場および地域別で最も早い成長を遂げるでしょうか？
コンバインドホルモン避妊薬の市場機会は、エンド市場の規模によってどのように異なりますか？
コンバインドホルモナルコントラセプティブのタイプと適用の内訳はどのようになりますか？
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの複合ホルモン避妊薬、年間売上、2019年～2030年
2.1.2 複合ホルモン避妊薬の世界市場の現状分析・将来予測、地理別、2019年、2023年および2030年
2.1.3 複合ホルモン避妊薬の世界市場の現状分析・将来予測、国・地域別、2019年、2023年および2030年
2.2 複合ホルモン避妊薬セグメント、タイプ別
2.2.1 15～24歳
2.2.2 25～34歳
2.2.3 35～44歳
2.2.4 44歳以上
2.3 複合ホルモン避妊薬の売上、タイプ別
2.3.1 グローバルにおける複合ホルモン避妊薬の売上・市場シェア、タイプ別（2019年～2024年）
2.3.2 複合ホルモン避妊薬のグローバルレベニュー・市場シェア、タイプ別（2019～2024年）
2.3.3 グローバルの複合ホルモン避妊薬、販売価格（タイプ別）（2019年～2024年）
2.4 複合ホルモン避妊薬セグメント、用途別
2.4.1 病院薬局
2.4.2 小売薬局
2.4.3 オンラインファーマシー
2.5 複合ホルモン避妊薬の売上、用途別
2.5.1 グローバルの複合ホルモン避妊薬、収益・市場シェア（用途別）（2019年～2024年）
2.5.2 複合ホルモン避妊薬のグローバルレベニュー・市場シェア、用途別（2019～2024年）
2.5.3 グローバルの複合ホルモン避妊薬、販売価格（用途別）（2019年～2024年）
3 グローバルにおける複合ホルモン避妊薬、企業別
3.1 グローバルにおける複合ホルモン避妊薬市場のブレークダウンデータ、企業別
3.1.1 グローバルにおける複合ホルモン避妊薬の年間売上、企業別（2019年～2024年）
3.1.2 グローバルにおける複合ホルモン避妊薬の売上・市場シェア、企業別（2019年～2024年）
3.2 グローバルにおける複合ホルモン避妊薬の年間収益、企業別（2019年～2024年）
3.2.1 グローバルにおける複合ホルモン避妊薬市場の収益規模、企業別（2019年～2024年）
3.2.2 グローバルにおける複合ホルモン避妊薬市場の収益シェア、企業別（2019年～2024年）
3.3 グローバルにおける複合ホルモン避妊薬の販売価格、企業別
3.4 複合ホルモン避妊薬の主要メーカー、生産地域分布、販売地域、製品タイプ
3.4.1 複合ホルモン避妊薬の主要メーカー、製品と拠点の分布
3.4.2 プレイヤーが提供している複合ホルモン避妊薬製品
3.5 市場集中度分析
3.5.1 競合情勢分析
3.5.2 集中度レシオ（CR3、CR5、CR10）（2019年～2024年）
3.6 新製品・潜在的参入
3.7 M&A、拡大
4 複合ホルモン避妊薬の世界市場過去推移レビュー、地理別
4.1 複合ホルモン避妊薬の世界市場規模の過去推移、地理別（2019年～2024年）
4.1.1 グローバルにおける複合ホルモン避妊薬の年間売上、地理別（2019年～2024年）
4.1.2 グローバルにおける複合ホルモン避妊薬の年間収益、地理別（2019年～2024年）
4.2 複合ホルモン避妊薬の世界市場規模の過去推移、国・地域別（2019年～2024年）
4.2.1 グローバルにおける複合ホルモン避妊薬の年間売上、国・地域別（2019年～2024年）
4.2.2 グローバルにおける複合ホルモン避妊薬の年間収益、国・地域別（2019年～2024年）
4.3 アメリカズにおける複合ホルモン避妊薬の売上成長
4.4 APACにおける複合ホルモン避妊薬の売上成長
4.5 ヨーロッパにおける複合ホルモン避妊薬の売上成長
4.6 中東・アフリカにおける複合ホルモン避妊薬の売上成長
5 アメリカズ
5.1 アメリカズにおける複合ホルモン避妊薬の売上、国別
5.1.1 アメリカズにおける複合ホルモン避妊薬の売上規模、国別（2019年～2024年）
5.1.2 アメリカズにおける複合ホルモン避妊薬市場の収益規模、国別（2019年～2024年）
5.2 アメリカズにおける複合ホルモン避妊薬の売上、タイプ別
5.3 アメリカズにおける複合ホルモン避妊薬の売上、用途別
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける複合ホルモン避妊薬の売上、地域別
6.1.1 APACにおける複合ホルモン避妊薬の売上規模、地域別（2019年～2024年）
6.1.2 APACにおける複合ホルモン避妊薬市場の収益規模、地域別（2019年～2024年）
6.2 APACにおける複合ホルモン避妊薬の売上、タイプ別
6.3 APACにおける複合ホルモン避妊薬の売上、用途別
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
6.10 中国の台湾
7 ヨーロッパ
7.1 ヨーロッパにおける複合ホルモン避妊薬、国別
7.1.1 ヨーロッパにおける複合ホルモン避妊薬の売上規模、国別（2019年～2024年）
7.1.2 ヨーロッパにおける複合ホルモン避妊薬市場の収益規模、国別（2019年～2024年）
7.2 ヨーロッパにおける複合ホルモン避妊薬の売上、タイプ別
7.3 ヨーロッパにおける複合ホルモン避妊薬の売上、用途別
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカにおける複合ホルモン避妊薬、国別
8.1.1 中東・アフリカにおける複合ホルモン避妊薬の売上規模、国別（2019年～2024年）
8.1.2 中東・アフリカにおける複合ホルモン避妊薬市場の収益規模、国別（2019年～2024年）
8.2 中東・アフリカにおける複合ホルモン避妊薬の売上、タイプ別
8.3 中東・アフリカにおける複合ホルモン避妊薬の売上、用途別
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 製造コスト構造分析
10.1 原料・サプライヤー
10.2 複合ホルモン避妊薬の製造コスト構造分析
10.3 複合ホルモン避妊薬の製造プロセス分析
10.4 複合ホルモン避妊薬のインダストリーチェーン構造
11 マーケティング・流通・顧客
11.1 販売チャネル
11.1.1 直接チャネル
11.1.2 間接チャネル
11.2 複合ホルモン避妊薬の流通業者
11.3 複合ホルモン避妊薬の顧客
12 複合ホルモン避妊薬の世界市場予測レビュー、地理別
12.1 グローバルにおける複合ホルモン避妊薬の市場規模予測、地域別
12.1.1 グローバルの複合ホルモン避妊薬、市場予測（地域別）（2025年～2030年）
12.1.2 グローバルの複合ホルモン避妊薬、年間収益予測（地域別）（2025年～2030年）
12.2 アメリカズにおける予測、国別
12.3 APACにおける予測、地域別
12.4 ヨーロッパにおける予測、国別
12.5 中東・アフリカにおける予測、国別
12.6 グローバルにおける複合ホルモン避妊薬の市場予測、タイプ別
12.7 グローバルにおける複合ホルモン避妊薬の市場予測、用途別
13 キープレイヤー分析
13.1 Actavis
13.1.1 Actavis：企業情報
13.1.2 Actavis：複合ホルモン避妊薬製品ポートフォリオと特徴
13.1.3 Actavis：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.1.4 Actavis：主要事業概要
13.1.5 Actavis：直近の展開
13.2 Agile Therapeutics
13.2.1 Agile Therapeutics：企業情報
13.2.2 Agile Therapeutics：複合ホルモン避妊薬製品ポートフォリオと特徴
13.2.3 Agile Therapeutics：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.2.4 Agile Therapeutics：主要事業概要
13.2.5 Agile Therapeutics：直近の展開
13.3 Allergan
13.3.1 Allergan：企業情報
13.3.2 Allergan：複合ホルモン避妊薬製品ポートフォリオと特徴
13.3.3 Allergan：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.3.4 Allergan：主要事業概要
13.3.5 Allergan：直近の展開
13.4 Bayer
13.4.1 Bayer：企業情報
13.4.2 Bayer：複合ホルモン避妊薬製品ポートフォリオと特徴
13.4.3 Bayer：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.4.4 Bayer：主要事業概要
13.4.5 Bayer：直近の展開
13.5 Teva Pharmaceutical Industries
13.5.1 Teva Pharmaceutical Industries：企業情報
13.5.2 Teva Pharmaceutical Industries：複合ホルモン避妊薬製品ポートフォリオと特徴
13.5.3 Teva Pharmaceutical Industries：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.5.4 Teva Pharmaceutical Industries：主要事業概要
13.5.5 Teva Pharmaceutical Industries：直近の展開
13.6 ANI Pharmaceuticals
13.6.1 ANI Pharmaceuticals：企業情報
13.6.2 ANI Pharmaceuticals：複合ホルモン避妊薬製品ポートフォリオと特徴
13.6.3 ANI Pharmaceuticals：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.6.4 ANI Pharmaceuticals：主要事業概要
13.6.5 ANI Pharmaceuticals：直近の展開
13.7 Ortho-McNeil-Janssen Pharmaceuticals
13.7.1 Ortho-McNeil-Janssen Pharmaceuticals：企業情報
13.7.2 Ortho-McNeil-Janssen Pharmaceuticals：複合ホルモン避妊薬製品ポートフォリオと特徴
13.7.3 Ortho-McNeil-Janssen Pharmaceuticals：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.7.4 Ortho-McNeil-Janssen Pharmaceuticals：主要事業概要
13.7.5 Ortho-McNeil-Janssen Pharmaceuticals：直近の展開
13.8 Noven Pharmaceuticals
13.8.1 Noven Pharmaceuticals：企業情報
13.8.2 Noven Pharmaceuticals：複合ホルモン避妊薬製品ポートフォリオと特徴
13.8.3 Noven Pharmaceuticals：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.8.4 Noven Pharmaceuticals：主要事業概要
13.8.5 Noven Pharmaceuticals：直近の展開
13.9 Johnson & Johnson
13.9.1 Johnson & Johnson：企業情報
13.9.2 Johnson & Johnson：複合ホルモン避妊薬製品ポートフォリオと特徴
13.9.3 Johnson & Johnson：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.9.4 Johnson & Johnson：主要事業概要
13.9.5 Johnson & Johnson：直近の展開
13.10 Mylan
13.10.1 Mylan：企業情報
13.10.2 Mylan：複合ホルモン避妊薬製品ポートフォリオと特徴
13.10.3 Mylan：複合ホルモン避妊薬売上・収益・価格およびグロスマージン（2019年～2024年）
13.10.4 Mylan：主要事業概要
13.10.5 Mylan：直近の展開
14 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The research report highlights the growth potential of the global Combined Hormonal Contraceptives market. Combined Hormonal Contraceptives are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Combined Hormonal Contraceptives. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Combined Hormonal Contraceptives market.
Combined hormonal contraceptives are used to prevent pregnancies. They are also used in the treatment of acne vulgaris, endometriosis, polycystic ovarian syndrome, and irregular menstrual flow by blocking ovulation. These products are widely used by women of aged between 15 and 49 years.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Combined Hormonal Contraceptives market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Combined Hormonal Contraceptives market. It may include historical data, market segmentation by Type (e.g., 15-24 years, 25-34 years), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Combined Hormonal Contraceptives market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Combined Hormonal Contraceptives market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Combined Hormonal Contraceptives industry. This include advancements in Combined Hormonal Contraceptives technology, Combined Hormonal Contraceptives new entrants, Combined Hormonal Contraceptives new investment, and other innovations that are shaping the future of Combined Hormonal Contraceptives.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Combined Hormonal Contraceptives market. It includes factors influencing customer ' purchasing decisions, preferences for Combined Hormonal Contraceptives product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Combined Hormonal Contraceptives market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Combined Hormonal Contraceptives market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Combined Hormonal Contraceptives market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Combined Hormonal Contraceptives industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Combined Hormonal Contraceptives market.
Market Segmentation:
Combined Hormonal Contraceptives market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
15-24 years
25-34 years
35-44 years
Above 44 years
Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Actavis
Agile Therapeutics
Allergan
Bayer
Teva Pharmaceutical Industries
ANI Pharmaceuticals
Ortho-McNeil-Janssen Pharmaceuticals
Noven Pharmaceuticals
Johnson & Johnson
Mylan
Key Questions Addressed in this Report
What is the 10-year outlook for the global Combined Hormonal Contraceptives market?
What factors are driving Combined Hormonal Contraceptives market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Combined Hormonal Contraceptives market opportunities vary by end market size?
How does Combined Hormonal Contraceptives break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Combined Hormonal Contraceptives Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Combined Hormonal Contraceptives by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Combined Hormonal Contraceptives by Country/Region, 2019, 2023 & 2030
2.2 Combined Hormonal Contraceptives Segment by Type
2.2.1 15-24 years
2.2.2 25-34 years
2.2.3 35-44 years
2.2.4 Above 44 years
2.3 Combined Hormonal Contraceptives Sales by Type
2.3.1 Global Combined Hormonal Contraceptives Sales Market Share by Type (2019-2024)
2.3.2 Global Combined Hormonal Contraceptives Revenue and Market Share by Type (2019-2024)
2.3.3 Global Combined Hormonal Contraceptives Sale Price by Type (2019-2024)
2.4 Combined Hormonal Contraceptives Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Combined Hormonal Contraceptives Sales by Application
2.5.1 Global Combined Hormonal Contraceptives Sale Market Share by Application (2019-2024)
2.5.2 Global Combined Hormonal Contraceptives Revenue and Market Share by Application (2019-2024)
2.5.3 Global Combined Hormonal Contraceptives Sale Price by Application (2019-2024)
3 Global Combined Hormonal Contraceptives by Company
3.1 Global Combined Hormonal Contraceptives Breakdown Data by Company
3.1.1 Global Combined Hormonal Contraceptives Annual Sales by Company (2019-2024)
3.1.2 Global Combined Hormonal Contraceptives Sales Market Share by Company (2019-2024)
3.2 Global Combined Hormonal Contraceptives Annual Revenue by Company (2019-2024)
3.2.1 Global Combined Hormonal Contraceptives Revenue by Company (2019-2024)
3.2.2 Global Combined Hormonal Contraceptives Revenue Market Share by Company (2019-2024)
3.3 Global Combined Hormonal Contraceptives Sale Price by Company
3.4 Key Manufacturers Combined Hormonal Contraceptives Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Combined Hormonal Contraceptives Product Location Distribution
3.4.2 Players Combined Hormonal Contraceptives Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Combined Hormonal Contraceptives by Geographic Region
4.1 World Historic Combined Hormonal Contraceptives Market Size by Geographic Region (2019-2024)
4.1.1 Global Combined Hormonal Contraceptives Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Combined Hormonal Contraceptives Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Combined Hormonal Contraceptives Market Size by Country/Region (2019-2024)
4.2.1 Global Combined Hormonal Contraceptives Annual Sales by Country/Region (2019-2024)
4.2.2 Global Combined Hormonal Contraceptives Annual Revenue by Country/Region (2019-2024)
4.3 Americas Combined Hormonal Contraceptives Sales Growth
4.4 APAC Combined Hormonal Contraceptives Sales Growth
4.5 Europe Combined Hormonal Contraceptives Sales Growth
4.6 Middle East & Africa Combined Hormonal Contraceptives Sales Growth
5 Americas
5.1 Americas Combined Hormonal Contraceptives Sales by Country
5.1.1 Americas Combined Hormonal Contraceptives Sales by Country (2019-2024)
5.1.2 Americas Combined Hormonal Contraceptives Revenue by Country (2019-2024)
5.2 Americas Combined Hormonal Contraceptives Sales by Type
5.3 Americas Combined Hormonal Contraceptives Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Combined Hormonal Contraceptives Sales by Region
6.1.1 APAC Combined Hormonal Contraceptives Sales by Region (2019-2024)
6.1.2 APAC Combined Hormonal Contraceptives Revenue by Region (2019-2024)
6.2 APAC Combined Hormonal Contraceptives Sales by Type
6.3 APAC Combined Hormonal Contraceptives Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Combined Hormonal Contraceptives by Country
7.1.1 Europe Combined Hormonal Contraceptives Sales by Country (2019-2024)
7.1.2 Europe Combined Hormonal Contraceptives Revenue by Country (2019-2024)
7.2 Europe Combined Hormonal Contraceptives Sales by Type
7.3 Europe Combined Hormonal Contraceptives Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Combined Hormonal Contraceptives by Country
8.1.1 Middle East & Africa Combined Hormonal Contraceptives Sales by Country (2019-2024)
8.1.2 Middle East & Africa Combined Hormonal Contraceptives Revenue by Country (2019-2024)
8.2 Middle East & Africa Combined Hormonal Contraceptives Sales by Type
8.3 Middle East & Africa Combined Hormonal Contraceptives Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Combined Hormonal Contraceptives
10.3 Manufacturing Process Analysis of Combined Hormonal Contraceptives
10.4 Industry Chain Structure of Combined Hormonal Contraceptives
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Combined Hormonal Contraceptives Distributors
11.3 Combined Hormonal Contraceptives Customer
12 World Forecast Review for Combined Hormonal Contraceptives by Geographic Region
12.1 Global Combined Hormonal Contraceptives Market Size Forecast by Region
12.1.1 Global Combined Hormonal Contraceptives Forecast by Region (2025-2030)
12.1.2 Global Combined Hormonal Contraceptives Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Combined Hormonal Contraceptives Forecast by Type
12.7 Global Combined Hormonal Contraceptives Forecast by Application
13 Key Players Analysis
13.1 Actavis
13.1.1 Actavis Company Information
13.1.2 Actavis Combined Hormonal Contraceptives Product Portfolios and Specifications
13.1.3 Actavis Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Actavis Main Business Overview
13.1.5 Actavis Latest Developments
13.2 Agile Therapeutics
13.2.1 Agile Therapeutics Company Information
13.2.2 Agile Therapeutics Combined Hormonal Contraceptives Product Portfolios and Specifications
13.2.3 Agile Therapeutics Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Agile Therapeutics Main Business Overview
13.2.5 Agile Therapeutics Latest Developments
13.3 Allergan
13.3.1 Allergan Company Information
13.3.2 Allergan Combined Hormonal Contraceptives Product Portfolios and Specifications
13.3.3 Allergan Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Allergan Main Business Overview
13.3.5 Allergan Latest Developments
13.4 Bayer
13.4.1 Bayer Company Information
13.4.2 Bayer Combined Hormonal Contraceptives Product Portfolios and Specifications
13.4.3 Bayer Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Bayer Main Business Overview
13.4.5 Bayer Latest Developments
13.5 Teva Pharmaceutical Industries
13.5.1 Teva Pharmaceutical Industries Company Information
13.5.2 Teva Pharmaceutical Industries Combined Hormonal Contraceptives Product Portfolios and Specifications
13.5.3 Teva Pharmaceutical Industries Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Teva Pharmaceutical Industries Main Business Overview
13.5.5 Teva Pharmaceutical Industries Latest Developments
13.6 ANI Pharmaceuticals
13.6.1 ANI Pharmaceuticals Company Information
13.6.2 ANI Pharmaceuticals Combined Hormonal Contraceptives Product Portfolios and Specifications
13.6.3 ANI Pharmaceuticals Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 ANI Pharmaceuticals Main Business Overview
13.6.5 ANI Pharmaceuticals Latest Developments
13.7 Ortho-McNeil-Janssen Pharmaceuticals
13.7.1 Ortho-McNeil-Janssen Pharmaceuticals Company Information
13.7.2 Ortho-McNeil-Janssen Pharmaceuticals Combined Hormonal Contraceptives Product Portfolios and Specifications
13.7.3 Ortho-McNeil-Janssen Pharmaceuticals Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Ortho-McNeil-Janssen Pharmaceuticals Main Business Overview
13.7.5 Ortho-McNeil-Janssen Pharmaceuticals Latest Developments
13.8 Noven Pharmaceuticals
13.8.1 Noven Pharmaceuticals Company Information
13.8.2 Noven Pharmaceuticals Combined Hormonal Contraceptives Product Portfolios and Specifications
13.8.3 Noven Pharmaceuticals Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Noven Pharmaceuticals Main Business Overview
13.8.5 Noven Pharmaceuticals Latest Developments
13.9 Johnson & Johnson
13.9.1 Johnson & Johnson Company Information
13.9.2 Johnson & Johnson Combined Hormonal Contraceptives Product Portfolios and Specifications
13.9.3 Johnson & Johnson Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Johnson & Johnson Main Business Overview
13.9.5 Johnson & Johnson Latest Developments
13.10 Mylan
13.10.1 Mylan Company Information
13.10.2 Mylan Combined Hormonal Contraceptives Product Portfolios and Specifications
13.10.3 Mylan Combined Hormonal Contraceptives Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Mylan Main Business Overview
13.10.5 Mylan Latest Developments
14 Research Findings and Conclusion
List of Tables Table 1. Combined Hormonal Contraceptives Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions) Table 2. Combined Hormonal Contraceptives Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions) Table 3. Major Players of 15-24 years Table 4. Major Players of 25-34 years Table 5. Major Players of 35-44 years Table 6. Major Players of Above 44 years Table 7. Global Combined Hormonal Contraceptives Sales by Type (2019-2024) & (Units) Table 8. Global Combined Hormonal Contraceptives Sales Market Share by Type (2019-2024) Table 9. Global Combined Hormonal Contraceptives Revenue by Type (2019-2024) & ($ million) Table 10. Global Combined Hormonal Contraceptives Revenue Market Share by Type (2019-2024) Table 11. Global Combined Hormonal Contraceptives Sale Price by Type (2019-2024) & (USD/Unit) Table 12. Global Combined Hormonal Contraceptives Sales by Application (2019-2024) & (Units) Table 13. Global Combined Hormonal Contraceptives Sales Market Share by Application (2019-2024) Table 14. Global Combined Hormonal Contraceptives Revenue by Application (2019-2024) Table 15. Global Combined Hormonal Contraceptives Revenue Market Share by Application (2019-2024) Table 16. Global Combined Hormonal Contraceptives Sale Price by Application (2019-2024) & (USD/Unit) Table 17. Global Combined Hormonal Contraceptives Sales by Company (2019-2024) & (Units) Table 18. Global Combined Hormonal Contraceptives Sales Market Share by Company (2019-2024) Table 19. Global Combined Hormonal Contraceptives Revenue by Company (2019-2024) ($ Millions) Table 20. Global Combined Hormonal Contraceptives Revenue Market Share by Company (2019-2024) Table 21. Global Combined Hormonal Contraceptives Sale Price by Company (2019-2024) & (USD/Unit) Table 22. Key Manufacturers Combined Hormonal Contraceptives Producing Area Distribution and Sales Area Table 23. Players Combined Hormonal Contraceptives Products Offered Table 24. Combined Hormonal Contraceptives Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) Table 25. New Products and Potential Entrants Table 26. Mergers & Acquisitions, Expansion Table 27. Global Combined Hormonal Contraceptives Sales by Geographic Region (2019-2024) & (Units) Table 28. Global Combined Hormonal Contraceptives Sales Market Share Geographic Region (2019-2024) Table 29. Global Combined Hormonal Contraceptives Revenue by Geographic Region (2019-2024) & ($ millions) Table 30. Global Combined Hormonal Contraceptives Revenue Market Share by Geographic Region (2019-2024) Table 31. Global Combined Hormonal Contraceptives Sales by Country/Region (2019-2024) & (Units) Table 32. Global Combined Hormonal Contraceptives Sales Market Share by Country/Region (2019-2024) Table 33. Global Combined Hormonal Contraceptives Revenue by Country/Region (2019-2024) & ($ millions) Table 34. Global Combined Hormonal Contraceptives Revenue Market Share by Country/Region (2019-2024) Table 35. Americas Combined Hormonal Contraceptives Sales by Country (2019-2024) & (Units) Table 36. Americas Combined Hormonal Contraceptives Sales Market Share by Country (2019-2024) Table 37. Americas Combined Hormonal Contraceptives Revenue by Country (2019-2024) & ($ Millions) Table 38. Americas Combined Hormonal Contraceptives Revenue Market Share by Country (2019-2024) Table 39. Americas Combined Hormonal Contraceptives Sales by Type (2019-2024) & (Units) Table 40. Americas Combined Hormonal Contraceptives Sales by Application (2019-2024) & (Units) Table 41. APAC Combined Hormonal Contraceptives Sales by Region (2019-2024) & (Units) Table 42. APAC Combined Hormonal Contraceptives Sales Market Share by Region (2019-2024) Table 43. APAC Combined Hormonal Contraceptives Revenue by Region (2019-2024) & ($ Millions) Table 44. APAC Combined Hormonal Contraceptives Revenue Market Share by Region (2019-2024) Table 45. APAC Combined Hormonal Contraceptives Sales by Type (2019-2024) & (Units) Table 46. APAC Combined Hormonal Contraceptives Sales by Application (2019-2024) & (Units) Table 47. Europe Combined Hormonal Contraceptives Sales by Country (2019-2024) & (Units) Table 48. Europe Combined Hormonal Contraceptives Sales Market Share by Country (2019-2024) Table 49. Europe Combined Hormonal Contraceptives Revenue by Country (2019-2024) & ($ Millions) Table 50. Europe Combined Hormonal Contraceptives Revenue Market Share by Country (2019-2024) Table 51. Europe Combined Hormonal Contraceptives Sales by Type (2019-2024) & (Units) Table 52. Europe Combined Hormonal Contraceptives Sales by Application (2019-2024) & (Units) Table 53. Middle East & Africa Combined Hormonal Contraceptives Sales by Country (2019-2024) & (Units) Table 54. Middle East & Africa Combined Hormonal Contraceptives Sales Market Share by Country (2019-2024) Table 55. Middle East & Africa Combined Hormonal Contraceptives Revenue by Country (2019-2024) & ($ Millions) Table 56. Middle East & Africa Combined Hormonal Contraceptives Revenue Market Share by Country (2019-2024) Table 57. Middle East & Africa Combined Hormonal Contraceptives Sales by Type (2019-2024) & (Units) Table 58. Middle East & Africa Combined Hormonal Contraceptives Sales by Application (2019-2024) & (Units) Table 59. Key Market Drivers & Growth Opportunities of Combined Hormonal Contraceptives Table 60. Key Market Challenges & Risks of Combined Hormonal Contraceptives Table 61. Key Industry Trends of Combined Hormonal Contraceptives Table 62. Combined Hormonal Contraceptives Raw Material Table 63. Key Suppliers of Raw Materials Table 64. Combined Hormonal Contraceptives Distributors List Table 65. Combined Hormonal Contraceptives Customer List Table 66. Global Combined Hormonal Contraceptives Sales Forecast by Region (2025-2030) & (Units) Table 67. Global Combined Hormonal Contraceptives Revenue Forecast by Region (2025-2030) & ($ millions) Table 68. Americas Combined Hormonal Contraceptives Sales Forecast by Country (2025-2030) & (Units) Table 69. Americas Combined Hormonal Contraceptives Revenue Forecast by Country (2025-2030) & ($ millions) Table 70. APAC Combined Hormonal Contraceptives Sales Forecast by Region (2025-2030) & (Units) Table 71. APAC Combined Hormonal Contraceptives Revenue Forecast by Region (2025-2030) & ($ millions) Table 72. Europe Combined Hormonal Contraceptives Sales Forecast by Country (2025-2030) & (Units) Table 73. Europe Combined Hormonal Contraceptives Revenue Forecast by Country (2025-2030) & ($ millions) Table 74. Middle East & Africa Combined Hormonal Contraceptives Sales Forecast by Country (2025-2030) & (Units) Table 75. Middle East & Africa Combined Hormonal Contraceptives Revenue Forecast by Country (2025-2030) & ($ millions) Table 76. Global Combined Hormonal Contraceptives Sales Forecast by Type (2025-2030) & (Units) Table 77. Global Combined Hormonal Contraceptives Revenue Forecast by Type (2025-2030) & ($ Millions) Table 78. Global Combined Hormonal Contraceptives Sales Forecast by Application (2025-2030) & (Units) Table 79. Global Combined Hormonal Contraceptives Revenue Forecast by Application (2025-2030) & ($ Millions) Table 80. Actavis Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 81. Actavis Combined Hormonal Contraceptives Product Portfolios and Specifications Table 82. Actavis Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 83. Actavis Main Business Table 84. Actavis Latest Developments Table 85. Agile Therapeutics Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 86. Agile Therapeutics Combined Hormonal Contraceptives Product Portfolios and Specifications Table 87. Agile Therapeutics Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 88. Agile Therapeutics Main Business Table 89. Agile Therapeutics Latest Developments Table 90. Allergan Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 91. Allergan Combined Hormonal Contraceptives Product Portfolios and Specifications Table 92. Allergan Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 93. Allergan Main Business Table 94. Allergan Latest Developments Table 95. Bayer Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 96. Bayer Combined Hormonal Contraceptives Product Portfolios and Specifications Table 97. Bayer Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 98. Bayer Main Business Table 99. Bayer Latest Developments Table 100. Teva Pharmaceutical Industries Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 101. Teva Pharmaceutical Industries Combined Hormonal Contraceptives Product Portfolios and Specifications Table 102. Teva Pharmaceutical Industries Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 103. Teva Pharmaceutical Industries Main Business Table 104. Teva Pharmaceutical Industries Latest Developments Table 105. ANI Pharmaceuticals Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 106. ANI Pharmaceuticals Combined Hormonal Contraceptives Product Portfolios and Specifications Table 107. ANI Pharmaceuticals Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 108. ANI Pharmaceuticals Main Business Table 109. ANI Pharmaceuticals Latest Developments Table 110. Ortho-McNeil-Janssen Pharmaceuticals Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 111. Ortho-McNeil-Janssen Pharmaceuticals Combined Hormonal Contraceptives Product Portfolios and Specifications Table 112. Ortho-McNeil-Janssen Pharmaceuticals Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 113. Ortho-McNeil-Janssen Pharmaceuticals Main Business Table 114. Ortho-McNeil-Janssen Pharmaceuticals Latest Developments Table 115. Noven Pharmaceuticals Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 116. Noven Pharmaceuticals Combined Hormonal Contraceptives Product Portfolios and Specifications Table 117. Noven Pharmaceuticals Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 118. Noven Pharmaceuticals Main Business Table 119. Noven Pharmaceuticals Latest Developments Table 120. Johnson & Johnson Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 121. Johnson & Johnson Combined Hormonal Contraceptives Product Portfolios and Specifications Table 122. Johnson & Johnson Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 123. Johnson & Johnson Main Business Table 124. Johnson & Johnson Latest Developments Table 125. Mylan Basic Information, Combined Hormonal Contraceptives Manufacturing Base, Sales Area and Its Competitors Table 126. Mylan Combined Hormonal Contraceptives Product Portfolios and Specifications Table 127. Mylan Combined Hormonal Contraceptives Sales (Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 128. Mylan Main Business Table 129. Mylan Latest Developments List of Figures Figure 1. Picture of Combined Hormonal Contraceptives Figure 2. Combined Hormonal Contraceptives Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Combined Hormonal Contraceptives Sales Growth Rate 2019-2030 (Units) Figure 7. Global Combined Hormonal Contraceptives Revenue Growth Rate 2019-2030 ($ Millions) Figure 8. Combined Hormonal Contraceptives Sales by Region (2019, 2023 & 2030) & ($ Millions) Figure 9. Product Picture of 15-24 years Figure 10. Product Picture of 25-34 years Figure 11. Product Picture of 35-44 years Figure 12. Product Picture of Above 44 years Figure 13. Global Combined Hormonal Contraceptives Sales Market Share by Type in 2023 Figure 14. Global Combined Hormonal Contraceptives Revenue Market Share by Type (2019-2024) Figure 15. Combined Hormonal Contraceptives Consumed in Hospital Pharmacy Figure 16. Global Combined Hormonal Contraceptives Market: Hospital Pharmacy (2019-2024) & (Units) Figure 17. Combined Hormonal Contraceptives Consumed in Retail Pharmacy Figure 18. Global Combined Hormonal Contraceptives Market: Retail Pharmacy (2019-2024) & (Units) Figure 19. Combined Hormonal Contraceptives Consumed in Online Pharmacy Figure 20. Global Combined Hormonal Contraceptives Market: Online Pharmacy (2019-2024) & (Units) Figure 21. Global Combined Hormonal Contraceptives Sales Market Share by Application (2023) Figure 22. Global Combined Hormonal Contraceptives Revenue Market Share by Application in 2023 Figure 23. Combined Hormonal Contraceptives Sales Market by Company in 2023 (Units) Figure 24. Global Combined Hormonal Contraceptives Sales Market Share by Company in 2023 Figure 25. Combined Hormonal Contraceptives Revenue Market by Company in 2023 ($ Million) Figure 26. Global Combined Hormonal Contraceptives Revenue Market Share by Company in 2023 Figure 27. Global Combined Hormonal Contraceptives Sales Market Share by Geographic Region (2019-2024) Figure 28. Global Combined Hormonal Contraceptives Revenue Market Share by Geographic Region in 2023 Figure 29. Americas Combined Hormonal Contraceptives Sales 2019-2024 (Units) Figure 30. Americas Combined Hormonal Contraceptives Revenue 2019-2024 ($ Millions) Figure 31. APAC Combined Hormonal Contraceptives Sales 2019-2024 (Units) Figure 32. APAC Combined Hormonal Contraceptives Revenue 2019-2024 ($ Millions) Figure 33. Europe Combined Hormonal Contraceptives Sales 2019-2024 (Units) Figure 34. Europe Combined Hormonal Contraceptives Revenue 2019-2024 ($ Millions) Figure 35. Middle East & Africa Combined Hormonal Contraceptives Sales 2019-2024 (Units) Figure 36. Middle East & Africa Combined Hormonal Contraceptives Revenue 2019-2024 ($ Millions) Figure 37. Americas Combined Hormonal Contraceptives Sales Market Share by Country in 2023 Figure 38. Americas Combined Hormonal Contraceptives Revenue Market Share by Country in 2023 Figure 39. Americas Combined Hormonal Contraceptives Sales Market Share by Type (2019-2024) Figure 40. Americas Combined Hormonal Contraceptives Sales Market Share by Application (2019-2024) Figure 41. United States Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 42. Canada Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 43. Mexico Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 44. Brazil Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 45. APAC Combined Hormonal Contraceptives Sales Market Share by Region in 2023 Figure 46. APAC Combined Hormonal Contraceptives Revenue Market Share by Regions in 2023 Figure 47. APAC Combined Hormonal Contraceptives Sales Market Share by Type (2019-2024) Figure 48. APAC Combined Hormonal Contraceptives Sales Market Share by Application (2019-2024) Figure 49. China Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 50. Japan Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 51. South Korea Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 52. Southeast Asia Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 53. India Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 54. Australia Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 55. China Taiwan Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 56. Europe Combined Hormonal Contraceptives Sales Market Share by Country in 2023 Figure 57. Europe Combined Hormonal Contraceptives Revenue Market Share by Country in 2023 Figure 58. Europe Combined Hormonal Contraceptives Sales Market Share by Type (2019-2024) Figure 59. Europe Combined Hormonal Contraceptives Sales Market Share by Application (2019-2024) Figure 60. Germany Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 61. France Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 62. UK Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 63. Italy Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 64. Russia Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 65. Middle East & Africa Combined Hormonal Contraceptives Sales Market Share by Country in 2023 Figure 66. Middle East & Africa Combined Hormonal Contraceptives Revenue Market Share by Country in 2023 Figure 67. Middle East & Africa Combined Hormonal Contraceptives Sales Market Share by Type (2019-2024) Figure 68. Middle East & Africa Combined Hormonal Contraceptives Sales Market Share by Application (2019-2024) Figure 69. Egypt Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 70. South Africa Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 71. Israel Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 72. Turkey Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 73. GCC Country Combined Hormonal Contraceptives Revenue Growth 2019-2024 ($ Millions) Figure 74. Manufacturing Cost Structure Analysis of Combined Hormonal Contraceptives in 2023 Figure 75. Manufacturing Process Analysis of Combined Hormonal Contraceptives Figure 76. Industry Chain Structure of Combined Hormonal Contraceptives Figure 77. Channels of Distribution Figure 78. Global Combined Hormonal Contraceptives Sales Market Forecast by Region (2025-2030) Figure 79. Global Combined Hormonal Contraceptives Revenue Market Share Forecast by Region (2025-2030) Figure 80. Global Combined Hormonal Contraceptives Sales Market Share Forecast by Type (2025-2030) Figure 81. Global Combined Hormonal Contraceptives Revenue Market Share Forecast by Type (2025-2030) Figure 82. Global Combined Hormonal Contraceptives Sales Market Share Forecast by Application (2025-2030) Figure 83. Global Combined Hormonal Contraceptives Revenue Market Share Forecast by Application (2025-2030)
